Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
about
Nanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Fundamental aspects of solid dispersion technology for poorly soluble drugsAn Intensified Vibratory Milling Process for Enhancing the Breakage Kinetics during the Preparation of Drug Nanosuspensions.Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs.Formation of Organic Molecular Nanocrystals under Soft Confinement.The Stabilization of Amorphous Zopiclone in an Amorphous Solid DispersionEupafolin nanoparticles protect HaCaT keratinocytes from particulate matter-induced inflammation and oxidative stress.Nanotherapeutics in the EU: an overview on current state and future directions.Theory and practice of supersaturatable formulations for poorly soluble drugs.Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A ReviewThermal Processing of PVP- and HPMC-Based Amorphous Solid Dispersions.Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-Soluble Drug Delivery (Part 2)Use of Polyvinyl Alcohol as a Solubility-Enhancing Polymer for Poorly Water Soluble Drug Delivery (Part 1).Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles.Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders.Bioavailability enhancement of a BCS IV compound via an amorphous combination product containing ritonavir.A recent trend of drug-nanoparticles in suspension for the application in drug delivery.Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products.Disintegration mediated controlled release supersaturating solid dispersion formulation of an insoluble drug: design, development, optimization, and in vitro evaluationPolymer/Amorphous Salt Solid Dispersions of Ciprofloxacin.Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.Melt extrusion with poorly soluble drugs - An integrated review.Crystallization of undercooled liquid fenofibrate.Unimolecular branched block copolymer nanoparticles in methanol for the preparation of poorly water-soluble drug nanoparticlesNanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability
P2860
Q26746912-B3A43D8B-4510-4D67-AABB-28A69D17F727Q26822873-196BB3E6-5722-4A0C-B4F0-35BF0F44C585Q30375813-94B7DA91-5D99-4BF1-A2E8-9E3E78093A1CQ35586493-2A1E0922-2573-4C14-AF3E-4757389BCBE0Q35981768-19ED7E14-A240-4721-8694-D14A71A0343BQ36360522-3185E446-51E6-4585-B5EF-99BD54B9084BQ37180037-6EC3D03B-8E4A-4D06-B7EB-7B00BB1D207DQ37601242-98E1A75A-1175-4BAC-A1E3-A0E579A83122Q38411345-B233B8E9-426F-4FF8-81D3-F5EF2294303FQ38573948-667A01D8-8638-4375-BB3B-4953C00B4F2BQ38619443-E7ED853E-3DFD-4929-BF6D-12250824D7F1Q38619498-ED0550D5-D4A1-4113-A8C4-37466C53DDE0Q38619585-993191DE-9163-4044-9769-ED956E064E53Q38687039-4F9CBA1C-563C-4F83-85D5-E86D3751E104Q38696042-B0578C01-4871-4029-9A87-F3C4B3300BFEQ38954732-8D849F80-6FE4-4B28-8BF6-F9BCC4037A2FQ38985268-E6E8F6AC-F2A3-42C8-A0C1-64E0646C9A39Q42012855-328AEEC9-283C-42DB-B08C-B45EC732FAD4Q42720527-05919C0E-AB0F-45BF-8FDE-DA8554D22ABDQ47898757-CE732DE2-23DC-4487-A3F7-ED896BFB3C46Q49092618-6DC8D389-EFD5-4038-B7A8-47A7D146CFE4Q50161058-904A00A0-B4CE-4EB3-B4D5-2FC7A1A8CD3FQ51671101-4865760D-DFD2-41C0-A4C5-84A35AACB768Q57369359-1CB34B01-DDDC-4C25-8021-DE74CC95420DQ58726467-8954D5FF-E87F-4494-83A1-B8D798272272
P2860
Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Amorphous solid dispersions an ...... y water-soluble drug delivery.
@en
type
label
Amorphous solid dispersions an ...... y water-soluble drug delivery.
@en
prefLabel
Amorphous solid dispersions an ...... y water-soluble drug delivery.
@en
P1476
Amorphous solid dispersions an ...... y water-soluble drug delivery.
@en
P2093
Chris Brough
R O Williams
P304
P356
10.1016/J.IJPHARM.2013.05.061
P407
P577
2013-06-07T00:00:00Z